Japan

Fuji Yakuhin

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe

Lead Product(s): Dotinurad

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Fortress Biotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 10, 2021

Details:

Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.

Taisho Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Chugai Pharma, Taisho Pharma Terminate Co-Marketing Agreement for Edirol to Treat Osteoporosis

Lead Product(s): Eldecalcitol

Therapeutic Area: Musculoskeletal Product Name: Edirol

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Chugai Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination January 22, 2021

Details:

Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg, a treatment for osteoporosis for which Chugai has a marketing authorization.